01 / Antibody intelligence, made actionable

Validation
starts in the tissue.

Monoclonal research antibodies for researchers, pathologists and biomarker teams who need evidence they can inspect.

Browse antibodies ↗How we validate ↗

Fluorescence multiplex immunohistochemistry of a normal human tonsil with anti-CD8 (DIA-TC8; orange/red) and anti-CD112R/PVRIG clone R12 (DIA-R12; green), nuclei blue – overlay with detail inset

Developed with histopathologyImmunohistochemistry integrated early in development.

Tissue-profiledPattern assessment across human normal and tumor tissues.

Published evidenceClone-specific peer-reviewed use, cited with DOI where available.

Multiplex IHCDocumented in multiplex settings for selected clones.

For Research Use Only. Not for use in diagnostic procedures.

01Find a markerTarget / clone / application 02Review validationApproach / evidence classes / research use 03Talk to supportScientific / partnership / order

02 Scientific finder

Find the right signal.

Six monoclonal clones for tissue-based immuno-oncology research — searchable by target, clone and application.

6 clones · RUO

TG-1 immunostaining on human tonsil at 100× (ONCOdianova reference image, Tech Note V1, Fig. 1).

TIGITClone TG1 · DIA-TG1-MClone-specifically published mouse monoclonal anti-TIGIT antibody for human FFPE, brightfield and fluorescence multiplex IHC. RRID AB_3750391.Product page ↗

Immunohistochemistry of human TIGIT in FFPE tonsil using clone TG2 – normal human tonsil with numerous TIGIT-positive lymphocytes (ONCOdianova reference image, datasheet DIA-TG2-M V05).

TIGITClone TG2 · DIA-TG2-MSeparate anti-TIGIT clone for IHC on human FFPE tissue. Kept strictly distinct from TG1.Product page ↗

CD112R / PVRIGClone R12 · DIA-R12Anti-CD112R/PVRIG antibody used in a peer-reviewed multiplex immunofluorescence study (Yang et al., Modern Pathology 2023).Product page ↗

Multicolor immunofluorescence of FOXP3 (red; anti-FOXP3 clone FX3, DIA-FX3) and CD112R/PVRIG (green), magnification 4×, normal human tonsil – figure 01 of the previous ONCOdianova FOXP3 gallery.

FOXP3Clone FX3 · DIA-FX3Nuclear FOXP3 detection in human FFPE tissue; used in a peer-reviewed automated multiplex IF study (Picard et al., Acta Neuropathologica 2023).Product page ↗

Immunohistochemistry of human CD8 with anti-CD8 clone TC8 (DIA-TC8) in FFPE tissue – dense infiltrate of CD8-positive lymphocytes in adenocarcinoma of the prostate; figure 01 of the previous ONCOdianova CD8 gallery.

CD8Clone TC8 · DIA-TC8Anti-CD8 antibody with five peer-reviewed clone-specific publications on large human tumor cohorts.Product page ↗

Immunohistochemistry of human CD73 (NT5E) with anti-CD73 clone KK3 (DIA-KK3) in FFPE tissue – strong homogeneous CD73 immunostaining in a cholangiocellular carcinoma of the liver; figure 01 of the previous ONCOdianova CD73 gallery.

CD73Clone KK3 · DIA-KK3Mouse monoclonal anti-CD73 (NT5E) antibody for IHC on routine human FFPE tissue; membranous staining pattern, tonsil as positive control; ten original ONCOdianova tissue figures.Product page ↗

CAL2 IHC across four MPN cases, two positive and two negative.

Mutant CALR (calreticulin)Clone CAL2® · dedicated siteCAL2® — mutation-specific antibody for mutant CALR. Dedicated scientific information, methodology, evidence and ordering information are available at cal2antibody.com. For Research Use Only. Not for diagnostic or therapeutic use.Explore CAL2® →

03 How we work

Four pillars. One standard.

Develop

Our idea is to integrate immunohistochemistry as early as possible in the hybridoma screening procedure and thereby expand the classical ELISA screen by histopathological expertise at an early stage of FFPE antibody development.

Validate

We use our strong network for histopathological validation of new targets in human tissues. This expands our expertise to develop new test systems for novel targets. For cancer immunology targets we put a focus on tumor infiltrating lymphocytes.

Improve

Multiplex Assay technology develops fast and depends on the availability of reliable antibody reagents. Our vision is to provide the best cancer immunology marker antibodies for combined use to improve the understanding of patient subpopulations.

Partner

Our objective is to potentially develop multiple clones for the same target by approaching one target at diverse immunogenic sites. We are able to reference mapped epitopes and open for beta testing opportunities with pharmaceutical partners.

04 Validation framework

A method you can
inspect.

Every product page documents peer-reviewed clone-specific evidence, congress abstracts and technical specifications, with references, catalog numbers and RRIDs where assigned.

Request a data package ↗

Evidence layer 01

Clone selection

Context-led clone evaluation with immunohistochemistry integrated early in development.

Evidence layer 02

Pattern profiling

Pattern assessment across human normal and tumor tissues with defined positive controls.

Evidence layer 03

Published evidence

Clone-specific use documented in peer-reviewed studies where available — each cited with DOI on the product page.

Designed for the question

From marker
to meaning.

Products are organised around the questions research teams actually ask: immune phenotype, checkpoint axes, spatial arrangement and tumour context.

Immuno-oncology markers
Multiplex IHC panels
FFPE tissue research

CD8 × CD112R multiplex · Human tonsil · Clones TC8 + R12

05 Ordering & next steps

Clear pathways for
every next step.

ONCOdianova products are available through our ordering partner BIOZOL and selected distributors. Every route maps a specialist question to a product, a document or a conversation.

ProductsBrowse the six research antibody clones OrderingOrder information and BIOZOL partner detailsDistributionFind a distributor in your region (in preparation)

For Research Use Only. Not for diagnostic or therapeutic use.